Staphylococcus vaccine

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
(Redirected from Staphylococcal vaccine)

Staphylococcus vaccine (Staphypan) has been proposed as an immunomodulatory therapy in the treatment of Chronic Fatigue Syndrome. It was first used in Sweden with patients who became ill after a 1957 outbreak of Asian flu.[1]

A Swedish study found significant improvement in Fibromyalgia and Chronic Fatigue Syndrome patients with a mean reduction in CPRS-15 scores of 50%.[2][3]

A second study found significantly increased capacity of serum to neutralise alpha-toxin and a significant increase in serum IgG to alpha-toxin and lipase in patients receiving Staphypan.[4]

Staphypan is no longer being commercially manufactured.[1] Another staphylococcal toxoid vaccine made by the Russian pharmaceutical company Medgamal is being used by some ME/CFS patients (see here), but it does not contain the same antigens as Staphypan. Its efficacy is unclear, but is thought to work to a degree, though less effective than Staphypan.

Staphylococcal vaccine favors Th1 dominance.[citation needed]

Learn more[edit | edit source]

See also[edit | edit source]

References[edit | edit source]

  1. 1.0 1.1 YouTube - Interview with Professor Carl-Gerhard Gottfries, Part 1: Background and Vaccine
  2. IACFS/ME - Immunotherapy of Fibromyalgia and Chronic Fatigue Syndrome by a Staphylococcus Toxoid Vaccine
  3. Zachrisson, Olof; Regland, Björn; Jahreskog, Marianne; Jonsson, Michael; Kron, Margareta; Gottfries, Carl-Gerhard (2002), "Treatment with staphylococcus toxoid in fibromyalgia/chronic fatigue syndrome--a randomised controlled trial", European Journal of Pain (London, England), 6 (6): 455–466, ISSN 1090-3801, PMID 12413434
  4. Zachrisson, O.; Colque-Navarro, P.; Gottfries, C.G.; Regland, B.; Möllby, R. (February 2004), "Immune modulation with a staphylococcal preparation in fibromyalgia/chronic fatigue syndrome: relation between antibody levels and clinical improvement", European Journal of Clinical Microbiology & Infectious Diseases: Official Publication of the European Society of Clinical Microbiology, 23 (2): 98–105, doi:10.1007/s10096-003-1062-8, ISSN 0934-9723, PMID 14735403